Prophase labs announces substantial growth expectations for pharmaloz manufacturing subsidiary due to skyrocketing demand for pharmaloz output.

Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter.

PRPH Ratings Summary

PRPH Quant Ranking